| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
Departments of Pathology [N. P., B. K-A., M. O., M. I.], Medicine [L. E. P.], Molecular and Human Genetics [L. E. P.], and Molecular and Cellular Biology [N. M. G.], Baylor College of Medicine and Houston Department of Veterans Affairs Medical Center, Houston, Texas 77030, and Department of Microbiology, New York University School of Medicine, New York, New York 10016 [S. O., C. B.]
Fibroblast growth factor (FGF) 2 (or basic FGF) is expressed at increased levels in human prostate cancer. FGF2 can promote cell motility and proliferation, increase tumor angiogenesis, and inhibit apoptosis, all of which play an important role in tumor progression. To determine whether FGF2 plays a critical role in prostate cancer progression, we have used the transgenic adenocarcinoma of the mouse prostate (TRAMP) model system. A high percentage of TRAMP mice develop metastatic prostate cancer, and thus the TRAMP model is useful for evaluating cancer progression. TRAMP mice were crossed with FGF2 knockout (FGF2-/-) mice, and tumor progression in TRAMP mice that were either hemi- or homozygous for inactivation of the FGF2 allele was compared with progression in wild-type TRAMP mice. Inactivation of even one FGF2 allele resulted in increased survival, a decrease in metastasis, and inhibition of progression to the poorly differentiated phenotype in primary prostatic tumors. When compared with wild-type mice, poorly differentiated tumors arising in FGF+/- and FGF-/- mice expressed higher levels of vascular endothelial growth factor and, in some cases, increased levels of acidic FGF intracellular binding protein, a nuclear FGF1-binding protein. These findings suggest that both FGF2-mediated angiogenesis and intranuclear FGF2 activities may promote tumor progression and support the hypothesis that FGF2 plays a significant role in prostate cancer progression in vivo.
This article has been cited by other articles:
|
|
 |
|
  L. Persano, L. Moserle, G. Esposito, V. Bronte, V. Barbieri, M. Iafrate, M. P. Gardiman, P. Larghero, U. Pfeffer, E. Naschberger, et al. Interferon-{alpha} counteracts the angiogenic switch and reduces tumor cell proliferation in a spontaneous model of prostatic cancer Carcinogenesis, May 1, 2009; 30(5): 851 - 860. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Cebulla, M.-E. Jockovich, Y. Pina, H. Boutrid, A. Alegret, A. Kulak, A. S. Hackam, S. K. Bhattacharya, W. J. Feuer, and T. G. Murray Basic Fibroblast Growth Factor Impact on Retinoblastoma Progression and Survival Invest. Ophthalmol. Vis. Sci., December 1, 2008; 49(12): 5215 - 5221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Yan, B. Bentley, and R. Shao Distinct Angiogenic Mediators Are Required for Basic Fibroblast Growth Factor- and Vascular Endothelial Growth Factor-induced Angiogenesis: The Role of Cytoplasmic Tyrosine Kinase c-Abl in Tumor Angiogenesis Mol. Biol. Cell, May 1, 2008; 19(5): 2278 - 2288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Cotton, M. K. O'Bryan, and B. T. Hinton Cellular Signaling by Fibroblast Growth Factors (FGFs) and Their Receptors (FGFRs) in Male Reproduction Endocr. Rev., April 1, 2008; 29(2): 193 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Lin, G. Liu, Y. Zhang, Y.-P. Hu, K. Yu, C. Lin, K. McKeehan, J. W. Xuan, D. M. Ornitz, M. M. Shen, et al. Fibroblast growth factor receptor 2 tyrosine kinase is required for prostatic morphogenesis and the acquisition of strict androgen dependency for adult tissue homeostasis Development, February 15, 2007; 134(4): 723 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Yan, C.-T. Yu, M. Ozen, M. Ittmann, S. Y. Tsai, and M.-J. Tsai Steroid Receptor Coactivator-3 and Activator Protein-1 Coordinately Regulate the Transcription of Components of the Insulin-Like Growth Factor/AKT Signaling Pathway. Cancer Res., November 15, 2006; 66(22): 11039 - 11046. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. B. Goodman Jr., M. Febbraio, R. Simantov, R. Zheng, R. Shen, R. L. Silverstein, and D. M. Nanus Neprilysin Inhibits Angiogenesis via Proteolysis of Fibroblast Growth Factor-2 J. Biol. Chem., November 3, 2006; 281(44): 33597 - 33605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hatziapostolou, C. Polytarchou, P. Katsoris, J. Courty, and E. Papadimitriou Heparin Affin Regulatory Peptide/Pleiotrophin Mediates Fibroblast Growth Factor 2 Stimulatory Effects on Human Prostate Cancer Cells J. Biol. Chem., October 27, 2006; 281(43): 32217 - 32226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. R. K. Loeb, J. L. Harris, and C. S. Craik Granzyme B Proteolyzes Receptors Important to Proliferation and Survival, Tipping the Balance toward Apoptosis J. Biol. Chem., September 22, 2006; 281(38): 28326 - 28335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. P. Milling Smith, S. Battersby, K. J. Sales, H. O. D. Critchley, and H. N. Jabbour Prostacyclin Receptor Up-Regulates the Expression of Angiogenic Genes in Human Endometrium via Cross Talk with Epidermal Growth Factor Receptor and the Extracellular Signaling Receptor Kinase 1/2 Pathway Endocrinology, April 1, 2006; 147(4): 1697 - 1705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Yang, J. A. Tuxhorn, S. J. Ressler, S. J. McAlhany, T. D. Dang, and D. R. Rowley Stromal Expression of Connective Tissue Growth Factor Promotes Angiogenesis and Prostate Cancer Tumorigenesis Cancer Res., October 1, 2005; 65(19): 8887 - 8895. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Stapelberg, N. Gellert, E. Swettenham, M. Tomasetti, P. K. Witting, A. Procopio, and J. Neuzil {alpha}-Tocopheryl Succinate Inhibits Malignant Mesothelioma by Disrupting the Fibroblast Growth Factor Autocrine Loop: MECHANISM AND THE ROLE OF OXIDATIVE STRESS J. Biol. Chem., July 8, 2005; 280(27): 25369 - 25376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ozen and M. Ittmann Increased Expression and Activity of CDC25C Phosphatase and an Alternatively Spliced Variant in Prostate Cancer Clin. Cancer Res., July 1, 2005; 11(13): 4701 - 4706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. V. Wesley, M. McGroarty, and A. Homoyouni Dipeptidyl Peptidase Inhibits Malignant Phenotype of Prostate Cancer Cells by Blocking Basic Fibroblast Growth Factor Signaling Pathway Cancer Res., February 15, 2005; 65(4): 1325 - 1334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B Kwabi-Addo, M Ozen, and M Ittmann The role of fibroblast growth factors and their receptors in prostate cancer Endocr. Relat. Cancer, December 1, 2004; 11(4): 709 - 724. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Shain Exogenous Fibroblast Growth Factors Maintain Viability, Promote Proliferation, and Suppress GADD45{alpha} and GAS6 Transcript Content of Prostate Cancer Cells Genetically Modified to Lack Endogenous FGF-2 Mol. Cancer Res., November 1, 2004; 2(11): 653 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Kwabi-Addo, J. Wang, H. Erdem, A. Vaid, P. Castro, G. Ayala, and M. Ittmann The Expression of Sprouty1, an Inhibitor of Fibroblast Growth Factor Signal Transduction, Is Decreased in Human Prostate Cancer Cancer Res., July 15, 2004; 64(14): 4728 - 4735. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
